Literature DB >> 16208163

Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability.

Eric B Elbogen1, Jeffrey W Swanson, Marvin S Swartz, Richard Van Dorn.   

Abstract

Although studies have consistently shown a strong relationship between medication nonadherence and substance abuse in psychotic disorders, less is understood about the mechanisms underlying this relationship. The purpose of this study was to examine whether the relationship between substance abuse and medication nonadherence in psychosis is mediated by depressive symptoms and social stability. Participants interviewed (N = 528) were adults with schizophrenia and related disorders receiving public mental health services in four US states. Multivariate analyses showed substance abuse, depressive symptoms, and living stability each contributed to medication nonadherence; thus, the relationship between substance abuse and medication adherence in psychotic disorders did not appear to be mediated by the selected variables. Instead, a robust association between depressive symptoms and medication adherence was found, attesting to the utility of assessing for depression when evaluating adherence among people with psychosis. Living instability was common and related to medication nonadherence, too, warranting further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16208163     DOI: 10.1097/01.nmd.0000180742.51075.70

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  12 in total

1.  The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.

Authors:  Robert R Conley; Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Bruce J Kinon
Journal:  Schizophr Res       Date:  2006-11-15       Impact factor: 4.939

2.  Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data.

Authors:  Stephen J Tueller; Pascal R Deboeck; Richard A Van Dorn
Journal:  J Behav Med       Date:  2016-02-27

3.  Criminal justice system involvement among people with schizophrenia.

Authors:  Greg Greenberg; Robert A Rosenheck; Steven K Erickson; Rani A Desai; Elina A Stefanovics; Marvin Swartz; Richard S E Keefe; Joe McEvoy; T Scott Stroup
Journal:  Community Ment Health J       Date:  2010-11-28

4.  Social stability and HIV risk behavior: evaluating the role of accumulated vulnerability.

Authors:  Danielle German; Carl A Latkin
Journal:  AIDS Behav       Date:  2012-01

Review 5.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

6.  Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand.

Authors:  Sirijit Suttajit; Sutrak Pilakanta
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

7.  Factors associated with medication adherence among psychiatric outpatients at substance abuse risk.

Authors:  Stephen Magura; Andrew Rosenblum; Chunki Fong
Journal:  Open Addict J       Date:  2011-11-11

Review 8.  Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness.

Authors:  Dawn I Velligan; Martha Sajatovic; Ainslie Hatch; Pavel Kramata; John P Docherty
Journal:  Patient Prefer Adherence       Date:  2017-03-03       Impact factor: 2.711

9.  Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia.

Authors:  Hong Liu-Seifert; David H Adams; Haya Ascher-Svanum; Douglas E Faries; Bruce J Kinon
Journal:  Patient Prefer Adherence       Date:  2007-12-20       Impact factor: 2.711

10.  Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Jonathan P Lacro; Christian R Dolder; Xiaomei Peng
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.